Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Sanofi

U.S. losses of exclusivity peak in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Financial Report: Sanofi
2Q Revenues: €8.2 billion (-6%)
2Q Earnings: €762 million (-26%)
YTD Revenues: €16.1 billion (-7%)
YTD Earnings: €1.8 billion (-74%)
Comments: Pharmaceutical sales were up 2% to €6.3 billion driven by the Rare Blood Disorder and Immunology franchises, which was offset by declines in Diabetes and Established Rx Products. Sanofi Genzyme sales were up 14% driven by Dupixent and consolidation of Bioverativ. Vaccines sales were down 16% to €811 million related to the Pentaxim supply constraint in China. Consumer Healthcare sales increased 4% with growth in Europe and Emerging Markets. Diabetes and Cardiovascular sales were down 16% with the global Diabetes franchise down 12%. U.S. losses of exclusivity peak in the quarter. Lantus sales were down 21% to €891 million. Lovenox sales decreased 2% to €377 million. Aprovel/Avapro sales decreased 6% to €171 million, and Renvela/Renagel sales decreased 57% to €100 million, due to competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters